Cardiac biomarkers gain greater approval from medical community
Despite remarkable advances in treatment, heart disease remains the leading cause of death among adults in the United States.
Consequently, the demand is growing for cardiac biomarkers, chemical reagents that provide prompt and accurate diagnosis of acute myocardial infarction (AMI), commonly known as a "heart attack".
New analysis by the healthcare group at Frost & Sullivan (www.healthcare.frost.com), U.S. Cardiac Marker Markets, indicates total revenues will grow from $230 million in 2000 to more than $281 million by 2007.
A major influence for revenue growth is the increasing reliance upon cardiac markers for triaging chest pains and greater acceptance of cardiac markers within the medical community.
"The best way to describe the markets for cardiac markers is by its dynamic stability following the redefinition of AMI by the American College of Cardiology (ACC) and the European Society of Cardiology (ESC)," says Manoj Kenkare, Frost & Sullivan healthcare research manager. "This new definition covers the continuum of myocardial injury and calls for AMI diagnosis using serum cardiac markers, resulting in an increased number of tests performed for chest pain triage."
With an increasing number of diagnoses and a declining death rate it appears as if more people are living with heart disease rather than dying from it. This translates to a greater number of people who will have suspicious chest pains, necessitating cardiac marker testing.
In the year 2000, 60 million Americans were living with some form of cardiovascular disease (CAD), and more than 7 million of them suffered at least one AMI.
"Among the diagnostic tools that are used in hospitals, cardiac markers are the best in diagnosing AMI," states Kenkare.
Frost & Sullivan presents the 2001 Marketing Engineering Awards to companies that have worked diligently to make a positive contribution to the cardiac markers industry. These market specific awards are presented to: Bayer Diagnostics, Biosite Diagnostics, Dade Behring Inc., Ortho-Clinical Diagnostics and Roche Diagnostics.
Frost & Sullivan is a global leader in international strategic market consulting and training. This ongoing research is part of the frost.com Clinical Diagnostics Monitor Service, which includes market analyses on the Asian Clinical Laboratory Instruments Markets and the U.S. Reference Laboratory Testing Market. For more information, contact Nick Mariottini at nmariottini@frost.com .
Source: Frost & Sullivan
Subscribe to our free e-mail newsletter.
Click for a free Buyer's Guide listing.